Skip to main content
Home > The Daily Extra > Company News

Chronological Index of : Company News

 Current Issue
  • COMPANY NEWS: ContraVir obtains HBV candidate, investment from Chimerix

    Chimerix Inc. (NASDAQ:CMRX) granted ContraVir Pharmaceuticals Inc. (OTCBB:CTRV) exclusive, worldwide rights to develop and commercialize CMX157 for HBV and HIV. Chimerix will receive up front 120,000 shares of ContraVir…

    Published on 12/18/2014
  • COMPANY NEWS: Merck acquires OncoEthix for BET inhibitor

    Merck & Co. Inc. (NYSE:MRK) will pay $110 million up front to acquire cancer play OncoEthix S.A. (Lausanne, Switzerland). OncoEthix shareholders are eligible for a further $265 million in milestones.OncoEthix's lead …

    Published on 12/18/2014
  • COMPANY NEWS: Novo Nordisk, Xencor in antibody deal

    Novo Nordisk A/S (CSE:NVO; NYSE:NVO) and Xencor Inc. (NASDAQ:XNCR) partnered to use Xencor's XmAb bispecific Fc domain technology and XmAb immune inhibitor technology to develop antibodies against an undisclosed Novo …

    Published on 12/18/2014
  • COMPANY NEWS: Roche to acquire Dutalys

    Roche (SIX:ROG; OTCQX:RHHBY) will acquire antibody developer Dutalys GmbH (Vienna, Austria) for $133.8 million in cash up front. Dutalys' shareholders are eligible for $355 million in undisclosed milestones. Roche …

    Published on 12/18/2014
  • COMPANY NEWS: SciClone will channel Medicines Co. drugs in China

    The Medicines Co. (NASDAQ:MDCO) granted SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) exclusive rights to promote cardiovascular drugs Cleviprex clevidipine and Angiomax bivalirudin in China.SciClone, which sells to a …

    Published on 12/18/2014
  • COMPANY NEWS: Takeda taps ex-Sanofi exec Plump as CMSO

    Takeda Pharmaceuticals Co. Ltd. (Tokyo:4502) named Andrew Plump as a new corporate officer and Chief Medical and Scientific Officer designate.Plump will join Takeda on Feb. 1, replacing CMSO Tadataka Yamada after a …

    Published on 12/18/2014
  • COMPANY NEWS: FDA approves Cerus' Intercept for plasma

    Cerus Corp. (NASDAQ:CERS) jumped $1.08 (23%) to $5.86 on Wednesday after FDA approved the company's Intercept Blood System for plasma. The plasma pathogen inactivation system using the light-activated compound …

    Published on 12/17/2014
  • COMPANY NEWS: FDA will review Apotex's Neulasta biosimilar

    Apotex Inc. (Toronto, Ontario) said FDA accepted for filing a regulatory application for a biosimilar of pegfilgrastim. The application was submitted under the 351(k) abbreviated approval pathway under the Biosimilar …

    Published on 12/17/2014
  • COMPANY NEWS: Flexus discloses financings

    Cancer immunotherapy play Flexus Biosciences Inc. (San Carlos, Calif.) said it has raised $38 million in two rounds of funding. Kleiner Perkins Caufield & Byers incubated the company and led its $13 million series A in …

    Published on 12/17/2014
  • COMPANY NEWS: Halozyme jumps on J&J partnership

    Halozyme Therapeutics Inc. (NASDAQ:HALO) added $1.01 (13%) to $8.65 on Wednesday after announcing a collaboration with the Janssen unit of Johnson & Johnson (NYSE:JNJ) to use the biotech's Enhanze rHuPH20 technology to …

    Published on 12/17/2014
  • COMPANY NEWS: Pozen falls on second complete response

    Pozen Inc. (NASDAQ:POZN) lost $0.93 (10%) to $8.10 after FDA issued a second complete response letter for the company's Yosprala combinations of aspirin and omeprazole for the secondary prevention of cardiovascular …

    Published on 12/17/2014
  • COMPANY NEWS: Shire borrows $2.1B, reportedly eyes NPS

    Shire plc (LSE:SHP; NASDAQ:SHPG) secured $2.1 billion in a revolving loan agreement amid speculation it was preparing to make an acquisition.Both Shire and NPS Pharmaceuticals Inc. (NASDAQ:NPSP) declined to comment on …

    Published on 12/17/2014
  • COMPANY NEWS: FDA approves Ipsen's Somatuline Depot for GEP-NETs

    FDA approved an sNDA under Priority Review for Somatuline Depot lanreotide acetate (ITM-014) from Ipsen Group (Euronext:IPN; Pink:IPSEY) to treat rare gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Ipsen …

    Published on 12/16/2014
  • COMPANY NEWS: Galapagos regains GLPG1205 rights from J&J

    Galapagos N.V. (Euronext:GLPG; Pink:GLPYY) said Johnson & Johnson (NYSE:JNJ) returned all rights to compounds targeting G protein-coupled receptor 84 (GPR84) covered under the companies' partnership, including GLPG1205,…

    Published on 12/16/2014
  • COMPANY NEWS: IQWiG finds no additional Eylea benefit in DME

    The German Institute for Quality and Efficiency in Health Care (IQWiG) said in a dossier assessment that an added benefit was not proven for Eylea aflibercept from Bayer AG (Xetra:BAYN) for visual impairment due to …

    Published on 12/16/2014
  • COMPANY NEWS: Veloxis sues FDA over tacrolimus delay

    Veloxis Pharmaceuticals A/S (CSE:VELO) filed suit in the U.S. District Court for the District of Columbia seeking an order requiring FDA to grant final approval to immunosuppressant Envarsus XR tacrolimus and allow …

    Published on 12/16/2014
  • COMPANY NEWS: Altshuler leaves Broad Institute for Vertex

    David Altshuler will leave the Broad Institute of MIT and Harvard to join Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) as EVP of global research and CSO, effective early next year. He will replace Peter Mueller, who …

    Published on 12/15/2014
  • COMPANY NEWS: Ex-Onyx CEO Coles, MIT's Lindquist launch Yumanity

    Former Onyx Pharmaceuticals Inc. CEO Tony Coles and Massachusetts Institute of Technology Professor Susan Lindquist have teamed up to launch Yumanity Therapeutics LLC (Cambridge, Mass.), a newco targeting protein …

    Published on 12/15/2014
  • COMPANY NEWS: Genentech submits NDA for melanoma combo

    The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) submitted an NDA to FDA for the combination of the MEK inhibitor cobimetinib plus the BRAF inhibitor Zelboraf vemurafenib to treat metastatic melanoma in patients …

    Published on 12/15/2014
  • COMPANY NEWS: Gilead poaches Genentech oncology exec

    Gilead Sciences Inc. (NASDAQ:GILD) hired Phillipe Bishop as SVP of hematology and oncology therapeutics. Bishop had been VP of product development and oncology at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) …

    Published on 12/15/2014
  • COMPANY NEWS: NantWorks, Sorrento form immuno-oncology JV

    Patrick Soon-Shiong's NantWorks LLC (Los Angeles, Calif.) and Sorrento Therapeutics Inc. (NASDAQ:SRNE) formed a joint venture to study cancer immunotherapies. The companies will jointly supply $20 million to create "The…

    Published on 12/15/2014
  • COMPANY NEWS: Pfizer, Opko in $295M growth hormone deal

    Opko Health Inc. (NYSE:OPK) gained $0.68 to $8.86 on Monday after granting Pfizer Inc. (NYSE:PFE) a worldwide license to commercialize the long-acting human growth hormone analog hGH-CTP.Opko will receive $295 million …

    Published on 12/15/2014
  • COMPANY NEWS: Bayer fails to block generic Nexavar in India

    The Supreme Court of India dismissed an appeal by Bayer AG (Xetra:BAYN) and upheld a compulsory license issued to Natco Pharma Ltd. (BSE:NATCO; NSE:NATCOPHARM) to manufacture and market a generic version of cancer drug …

    Published on 12/12/2014
  • COMPANY NEWS: FDA adds NSCLC to Cyramza's label

    FDA approved an sBLA under Priority Review from Eli Lilly and Co. (NYSE:LLY) for Cyramza ramucirumab to treat metastatic non-small cell lung cancer (NSCLC).The approval in combination with docetaxel is for patients …

    Published on 12/12/2014
  • COMPANY NEWS: Genentech promotes Varney to head of gRED

    The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) promoted Michael Varney to head of Genentech Research and Early Development (gRED), effective Jan. 1, 2015. He will succeed Richard Scheller, who will retire. …

    Published on 12/12/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993